Coya Therapeutics Reports Q1 2026 Financial Results with $7.2 Million Net Loss

Coya Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $7.2 million, a slight improvement from the $7.3 million loss recorded in the same period last year. The company generated collaboration revenue of $251,147, down from $257,884 in the prior year. Total operating expenses for the quarter were $7.9 million, a marginal decrease from $7.93 million in the previous year, primarily due to reduced research and development costs, which fell to $4.1 million from $5.2 million. This reduction was attributed to a decrease in external preclinical and clinical product candidate expenses, reflecting the timing of activities related to the company's investigational new drug (IND) applications.

Coya's financial position showed improvement, with cash and cash equivalents increasing to $50.7 million as of March 31, 2026, compared to $46.8 million at the end of 2025. The company’s total assets rose to $53.3 million, while total liabilities decreased significantly to $4.3 million from $6.9 million at the end of the previous fiscal year. The reduction in liabilities was largely due to a decrease in accrued expenses, which fell to $1.4 million from $3.6 million. The company’s stockholders' equity also increased to $49 million, up from $43 million, reflecting the issuance of new shares in a private placement that raised approximately $11.1 million in January 2026.

Strategically, Coya has been focused on advancing its lead product candidate, COYA 302, a Treg-enhancing biologic aimed at treating neurodegenerative diseases. The company is currently conducting the ALSTARS Trial, a Phase 2 clinical study for COYA 302 in patients with amyotrophic lateral sclerosis (ALS). In addition, Coya entered into a significant collaboration with Dr. Reddy's Laboratories, granting them exclusive rights to commercialize COYA 302 in certain territories. This partnership is expected to provide substantial milestone payments and royalties, contingent on the successful development and commercialization of the product.

Operationally, Coya has made notable progress in its research and development efforts, with a focus on enhancing the function of regulatory T cells (Tregs). The company has expanded its employee headcount to support its growing operations, although specific figures were not disclosed. Coya's management anticipates continued investment in research and development, which will likely lead to increased operating expenses in the coming quarters as the company seeks to advance its product candidates through clinical trials and regulatory approvals.

Looking ahead, Coya Therapeutics expects to incur significant expenses and operating losses as it continues to develop its product pipeline. The company has indicated that it will need to secure additional financing to support its operations and growth strategy, particularly as it aims to bring its product candidates to market. The management remains optimistic about the potential of its therapies and the ongoing collaborations, which are expected to play a crucial role in the company's future success.